'FDA Adcomm Votes In Favor Of Alnylam's New Indication For Onpattro' - Endpoint News Reported Earlier
Portfolio Pulse from Benzinga Newsdesk
The FDA advisory committee has voted in favor of a new indication for Alnylam's drug, Onpattro. This positive development could potentially expand the drug's market and boost Alnylam's revenues.
September 13, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's positive vote for a new indication for Alnylam's Onpattro could potentially expand the drug's market, leading to increased revenues for Alnylam.
The FDA's positive vote is a significant regulatory milestone for Alnylam. It could potentially expand the market for Onpattro, leading to increased sales and revenues for the company. This is likely to have a positive impact on Alnylam's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100